Zacks: Analysts Anticipate Alimera Sciences Inc (ALIM) Will Announce Earnings of -$0.06 Per Share

Analysts predict that Alimera Sciences Inc (NASDAQ:ALIM) will post earnings per share of ($0.06) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Alimera Sciences’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Alimera Sciences posted earnings per share of ($0.04) during the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The company is scheduled to report its next earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Alimera Sciences will report full year earnings of ($0.27) per share for the current year, with EPS estimates ranging from ($0.29) to ($0.25). For the next fiscal year, analysts forecast that the company will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.17) to ($0.11). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that follow Alimera Sciences.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Monday, July 30th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The firm had revenue of $10.92 million during the quarter, compared to analyst estimates of $10.78 million.

Several brokerages have issued reports on ALIM. B. Riley began coverage on shares of Alimera Sciences in a research report on Friday, June 29th. They issued a “buy” rating and a $2.75 price objective for the company. HC Wainwright set a $3.00 price objective on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 31st. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Finally, Cowen reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Alimera Sciences in a research report on Wednesday, September 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $2.44.

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Alimera Sciences by 28.5% during the second quarter. BlackRock Inc. now owns 272,248 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 60,327 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Alimera Sciences by 20.8% during the second quarter. Renaissance Technologies LLC now owns 574,000 shares of the biopharmaceutical company’s stock worth $562,000 after buying an additional 99,000 shares in the last quarter. Finally, Stonepine Capital Management LLC grew its position in shares of Alimera Sciences by 13.0% during the second quarter. Stonepine Capital Management LLC now owns 6,981,184 shares of the biopharmaceutical company’s stock worth $6,830,000 after buying an additional 801,151 shares in the last quarter. 51.85% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ALIM traded up $0.01 during trading hours on Monday, hitting $0.96. The stock had a trading volume of 36,920 shares, compared to its average volume of 152,029. The company has a quick ratio of 3.61, a current ratio of 3.85 and a debt-to-equity ratio of -0.60. Alimera Sciences has a 1-year low of $0.74 and a 1-year high of $1.46. The company has a market capitalization of $68.64 million, a price-to-earnings ratio of -3.32 and a beta of 1.51.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Featured Story: What strategies should day traders use to execute a trade?

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply